{"id":"NCT00734578","sponsor":"Shire","briefTitle":"Efficacy and Safety of SPD503 in Combination With Psychostimulants","officialTitle":"A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Dose Optimization Study Evaluating the Efficacy and Safety of SPD503 in Combination With Psychostimulants in Children and Adolescents Aged 6-17 Years With a Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-09-02","primaryCompletion":"2009-12-10","completion":"2009-12-10","firstPosted":"2008-08-14","resultsPosted":"2010-11-23","lastUpdate":"2021-06-14"},"enrollment":461,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["ADHD"],"interventions":[{"type":"DRUG","name":"SPD503-AM","otherNames":["Intuniv"]},{"type":"DRUG","name":"SPD503-PM","otherNames":["Intuniv"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"SPD503-AM","type":"EXPERIMENTAL"},{"label":"SPD503-PM","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess the efficacy and safety of SPD503 in subjects with ADHD when co-administered with psychostimulants in children and adolescents aged 6-17 years with a diagnosis of ADHD with a sub-optimal, partial response to stimulants.","primaryOutcome":{"measure":"Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Week 8 - Last Observation Carried Forward (LOCF)","timeFrame":"Baseline and weekly up to 8 weeks","effectByArm":[{"arm":"SPD503-AM + Psychostimulant","deltaMin":-20.4,"sd":12.77},{"arm":"SPD503-PM + Psychostimulant","deltaMin":-21,"sd":12.39},{"arm":"Placebo + Psychostimulant","deltaMin":-16,"sd":11.77}],"pValues":[{"comp":"OG000 vs OG002","p":"0.002"},{"comp":"OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":null},"locations":{"siteCount":61,"countries":["United States"]},"refs":{"pmids":["22176941","25245353"],"seeAlso":["http://www.fda.gov/opacom/7alerts.html","http://www.intuniv.com/documents/INTUNIV_Full_Prescribing_Information.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":150},"commonTop":["Headache","Somnolence","Upper respiratory tract infection","Fatigue","Insomnia"]}}